{
    "clinical_study": {
        "@rank": "33559", 
        "arm_group": [
            {
                "arm_group_label": "CC-122 + CC-223 +/- rituximab", 
                "arm_group_type": "Experimental", 
                "description": "CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days"
            }, 
            {
                "arm_group_label": "CC-122 + CC-292 +/- rituximab", 
                "arm_group_type": "Experimental", 
                "description": "CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days"
            }, 
            {
                "arm_group_label": "CC-292 + CC-223 +/- rituximab", 
                "arm_group_type": "Experimental", 
                "description": "CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days"
            }
        ], 
        "brief_summary": {
            "textblock": "First study, at multiple clinical centers, exploring the effects of different combinations\n      of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma\n      (DLBCL)"
        }, 
        "brief_title": "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma, Large B-Cell, Diffuse", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122,\n      CC-223 and CC-292 administered orally as doublets with or without rituximab, in subjects\n      with relapsed/refractory DLBCL who have failed standard therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Biopsy proven Diffuse large B-cell lymphoma (DLBCL) (including transformed low grade\n             lymphoma)\n\n          -  Relapsed or refractory to prior standard treatment regimens\n\n          -  At least one site of measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.\n\n          -  Subjects must have the following laboratory values:\n\n               -  Absolute Neutrophil Count (ANC) \u2265 1.5 x 109/L or \u2265 1.0 x 109/L (with bone marrow\n                  involvement with DLBCL)\n\n               -  Hemoglobin (Hgb) \u2265 8 g/dL.\n\n               -  Platelets \u2265 50 x 109/L without transfusion for 7 days.\n\n               -  Potassium within normal limits\n\n               -  Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and\n                  Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) \u2264 2.5 x\n                  Upper Limit of Normal (ULN) or \u2264 5.0 X ULN if liver tumor is present.\n\n               -  Serum bilirubin \u2264 1.5 x ULN.\n\n               -  Estimated serum creatinine clearance of \u2265 50 mL/min\n\n        Exclusion Criteria:\n\n          -  Symptomatic central nervous system involvement.\n\n          -  Known symptomatic acute or chronic pancreatitis.\n\n          -  Persistent diarrhea or malabsorption despite medical management.\n\n          -  Peripheral neuropathy \u2265 grade 2\n\n          -  Impaired cardiac function or clinically significant cardiac diseases\n\n          -  Subjects with diabetes on active treatment (for subjects treated on CC-223 containing\n             arms only)\n\n          -  Prior autologous stem cell transplant (ASCT) \u2264 3 months before first dose.\n\n          -  Prior allogeneic stem cell transplant with either standard or reduced intensity\n             conditioning.\n\n          -  Prior systemic cancer-directed treatments or investigational modalities \u2264 5 half\n             lives or 4 weeks prior to starting study drugs, whichever is shorter.\n\n          -  Subjects who have undergone major surgery \u2264 2 weeks prior to starting study drugs.\n\n          -  Women who are pregnant or breast feeding. Adults of reproductive potential not\n             willing to employ two forms of birth control.\n\n          -  Subjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV)\n             infection.\n\n          -  Subjects with treatment-related myelodysplastic syndrome.\n\n          -  History of concurrent second cancers requiring active, ongoing systemic treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031419", 
            "org_study_id": "CC-122-DLBCL-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "CC-122 + CC-223 +/- rituximab", 
                "description": "2mg or 3 mg administered orally once daily", 
                "intervention_name": "CC-122", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-122 + CC-223 +/- rituximab", 
                "description": "20mg or 30mg administered orally once daily.", 
                "intervention_name": "CC-223", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-122 + CC-223 +/- rituximab", 
                "description": "375 mg/m2 administered intravenously once every 28 days", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-122 + CC-292 +/- rituximab", 
                "description": "2mg or 3mg administered orally once daily.", 
                "intervention_name": "CC-122", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-122 + CC-292 +/- rituximab", 
                "description": "500 mg twice a day administered orally.", 
                "intervention_name": "CC-292", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-122 + CC-292 +/- rituximab", 
                "description": "375 mg/m2 administered intravenously once every 28 days", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-292 + CC-223 +/- rituximab", 
                "description": "20mg or 30mg per day administered orally daily.", 
                "intervention_name": "CC-223", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-292 + CC-223 +/- rituximab", 
                "description": "500 mg twice a day administered orally.", 
                "intervention_name": "CC-292", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CC-292 + CC-223 +/- rituximab", 
                "description": "375 mg/m2 administered intravenously once every 28 days", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "CC-122", 
            "CC-223", 
            "CC-292", 
            "Rituximab", 
            "Lymphoma", 
            "Diffuse Large B-Cell Lymphoma"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford Cancer Institute"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Lee Moffitt Cancer Center and Research"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "West Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 1Z5"
                    }, 
                    "name": "Princess Margaret, Lymphoma Clinic, Blood & Marrow Transplant Centre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon Cedex 08", 
                        "country": "France"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "INT-Istituto Nazionale Tumori"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Clinico Humanitas-Humanitas Cancer"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliera Citt\u00e0 della Salute e della Scienza-corso- Bramante"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "AMC"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands"
                    }, 
                    "name": "UMCG"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Erasmus"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "France", 
                "Italy", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-cell Lymphoma", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Michael Pourdehnad, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "France: Institutional Ethical Committee", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands:  Independent Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine safety profiles and dose-limiting toxicities of study drug combinations using NCI CTCAE v4.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "From the time of informed consent, throughout dosing period and for 28 days after the last dose of study drug."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031419"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tumor response rates using Cheson Revised Response Criteria for Malignant Lymphoma", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Every 2-3 months until proof of tumor progression"
            }, 
            {
                "description": "Area under the plasma concentration-time curve", 
                "measure": "Pharmacokinetics - CC-223 and CC-292 interaction", 
                "safety_issue": "No", 
                "time_frame": "Day 1, Day 15"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}